Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

NCT04752865 — Completed, 36 participants, Hellenic Cooperative Oncology Group

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT04752865
Status	Completed
Study type	Observational
Enrollment	36 (Actual)
Sponsor	Hellenic Cooperative Oncology Group (Other)
Conditions	Ovarian Cancer
Dates	start 2018-02-09, primary completion 2024-02-15, completion 2024-06-14, first posted 2021-02-12, last updated 2026-10-19
Locations	1 site in Greece

-Summary

EFFECTS OF CYTOTOXIC CHEMOTHERAPY AND PARP INHIBITION ON THE GENOMIC CONTEXTURE OF OVARIAN CANCER: TR_NACT_OV/17 In order to approach the above open questions, ultimately aiming in understanding the effects of cancer drugs on tumor biology and hence in selecting the proper drugs for the patients in the context of Precision Medicine, the objective of this study is to study the genomic characteristics of ovarian tumors before and after treatment with classic neoadjuvant chemotherapy (NACT) and with the more recently approved PARP inhibitor olaparib.

Expand all sections · Collapse all

+Outcome measures

Primary outcomes

assesment of genomic characteristics of ovarian tumors at the diagnosis [4 years]
assesment of genomic characteristics of ovarian tumors after treatment with neoadjuvant platinum-based chemotherapy [4 years]

+Eligibility

Sex: Female, ages: 18 Years to 80 Years

Inclusion Criteria:

* ovarian cancer eligible for neoadjuvant chemotherapy

Exclusion Criteria:

\-

+Locations (1)

Facility	City	Country	Status
Adamantia Nikolaidi	Athens	Greece

+Investigators

Adamantia Nikolaidi, Study chair, HECOG